Company Overview of Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc., a specialty pharmaceutical company, engages in the acquisition, development, licensing, and marketing of pharmaceutical products. The company focuses on cardiometabolic therapeutics. It offers LIVALO, which is an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B (Apo B), and triglycerides; and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. The company also provides LIPOFEN (fenofibrate capsules), which is indicated as an adjunctive therapy to diet to reduce elevated triglycerides and to increase high density lipoprotein cholesterol in adult patients...
530 Industrial Park Boulevard
Montgomery, AL 36117
Founded in 2001
Key Executives for Kowa Pharmaceuticals America, Inc.
Chairman, Chief Executive Officer and President
Vice President of Trade and Business Development
Vice President of Medical Affairs
Compensation as of Fiscal Year 2017.
Kowa Pharmaceuticals America, Inc. Key Developments
Kowa Pharmaceuticals America Inc. Wins $104.43 Million Federal Contract
Dec 6 17
Kowa Pharmaceuticals America Inc. won a $104,434,809 federal contract from the U.S. Department of Veterans Affairs National Acquisition Center for medical, dental and veterinary equipment and supplies.
Kowa Pharmaceuticals America, Inc. Announces INTREPID Trial Results in the Lancet HIV
Apr 20 17
Kowa Pharmaceuticals America, Inc. announced publication of results of the INTREPID Trial (HIV-infected patients and treatment with pitavastatin vs. pravastatin for Dyslipidemia) in The Lancet HIV. Results of the Phase 4 trial showed that LIVALO (pitavastatin) 4 mg was superior to pravastatin 40 mg in reducing LDL cholesterol (LDL-C) in adults with HIV and dyslipidemia and had a comparable safety profile. Dyslipidemia affects more than three-fourths of people with HIV, putting them at significantly increased risk for cardiovascular disease. However, treatment of elevated LDL cholesterol in this patient population is challenging because of drug interactions between statins and commonly used antiretroviral agents. The finding that LIVALO was more effective than pravastatin in lowering LDL cholesterol and was well tolerated in HIV patients with dyslipidemia suggests it could be a viable treatment option for managing dyslipidemia and contributing factors in adults with HIV. The INTREPID trial is the first to evaluate the efficacy and safety of LIVALO in this difficult-to-treat patient population. The results not only demonstrate that LIVALO is superior to pravastatin in lowering LDL cholesterol, but also in maintaining moderate-intensity LDL cholesterol reduction similar to the non-HIV infected adult population. Furthermore, LIVALO can be used in patients receiving complex antiretroviral therapy at the high dose of LIVALO because it is not mainly metabolized via the cytochrome P450 enzyme system. The prospective, randomized, double-blind, active-controlled, Phase 4 superiority trial enrolled adults with HIV (CD4 cell counts >200 cells/mm3 and HIV-1 RNA.
Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. Announces Settlement of Patent Litigation with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd
Jan 17 17
Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. announced that they have finalized as agreement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. To settle all outstanding patent litigation related to Livalo (potavastatin calcium) tablets. Under the terms of the agreement, Kowa and Nissan grants Zydus a license to Zydus’ generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|